Indrayani Biotech halts ₹50 cr rights issue indefinitely
The ₹49.90 crore capital raise, critical for the NPA-classified nano-cap, was supposed to shore up its balance sheet. Now there is no timeline.
What's new
- Indrayani Biotech indefinitely postponed its ₹49.90 cr rights issue after two extensions.
- The capital raise was critical for the company facing financial distress and NPA classification.
- No revised timeline provided; committee will announce later.
Why this matters
For a nano-cap with a market cap of ₹83 crore, a rights issue of ₹49.90 crore is nearly existential. The indefinite postponement without a new timeline raises serious doubts about the company's ability to raise capital and service its debt. This is a material negative event for a company already under NPA stress.
What we're watching
- Whether the company provides a revised timeline or abandons the issue entirely.
- Lender reaction. NPA classification may worsen if capital isn't raised.
- Stock price response given the issue's size relative to market cap.
The full read
Indrayani Biotech wanted to raise ₹49.90 crore to fix its balance sheet. It was a make-or-break move. The issue was 60% of its entire market cap. After two extensions, the company has now postponed the rights issue indefinitely. No revised timeline. The Rights Issue Committee will 'decide later'. For a company already classified as an NPA, with a debt/equity ratio of 1.89 and a PAT that fell 67% in the trailing period, that silence is the story. The capital raise was supposed to shore up liquidity. Now there is no capital. The stock, at a market cap of ₹83 crore, may now face a reassessment of risk. This isn't a delay. It's a signal.
Questions answered
- Why did Indrayani Biotech postpone the rights issue?
- The Rights Issue Committee decided to halt until further notice after previously extending the schedule twice. The company cited no specific reason, but the move follows financial distress and NPA classification.
- How large is the rights issue relative to the company's market cap?
- The ₹49.90 crore issue is about 60% of the current market cap of ₹83 crore, making it a pivotal event for solvency.
- What financial condition is the company in?
- Indrayani Biotech has been classified as an NPA and faces financial distress. Its trailing debt/equity is 1.89, and PAT declined 67% despite revenue growth of 102%.
- Is there a new timeline for the rights issue?
- No. The company said it will communicate a revised timeline separately after the committee finalises a new schedule.
- What happens if the rights issue fails?
- Without the ₹49.90 crore infusion, liquidity and solvency risks increase significantly for the nano-cap, potentially accelerating default.
- How did the market value the company before this?
- The market cap was ₹83 crore, implying the rights issue size was transformative. Nearly two-thirds of the company's equity value was at stake.